CGON
CG Oncology·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Consensus Rating "Buy"
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CGON
Cg Oncology, Inc.
A late-stage clinical biopharmaceutical company focused on treating bladder cancer
400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618
--
CG Oncology, Inc., was originally incorporated as a California corporation on September 24, 2010 and was subsequently re-incorporated as a Delaware corporation on November 30, 2017. The Company is a late-stage clinical biopharmaceutical company focused on the development and commercialization of cretostimogene grenadenorepvec, a potential bladder retention therapy for bladder cancer patients. Its main drug candidate is in development as an alternative to BCG for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC) and is currently undergoing clinical trials in the BCG non-responsive and early stage patient population.
Company Financials
EPS
CGON has released its 2025 Q3 earnings. EPS was reported at -0.57, versus the expected -0.56, missing expectations. The chart below visualizes how CGON has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CGON has released its 2025 Q3 earnings report, with revenue of 1.67M, reflecting a YoY change of 3774.42%, and net profit of -43.81M, showing a YoY change of -114.69%. The Sankey diagram below clearly presents CGON's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
